Kevin Olivieri

Kevin Olivieri currently serves as Principal Scientist at Apriori Bio since October 2023. Previously, Kevin held the position of Principal Scientist at Affinia Therapeutics from July 2020 to October 2023 and served as Senior Scientist during this time. Kevin's earlier experience includes roles as Exploratory Scientist at Homology Medicines, Inc. where AAV-derived gene therapy vectors were applied to rare diseases, and Senior Cell Biologist at Genocea Biosciences, focused on developing image-based platforms for vaccine candidate screening. Kevin also worked as Staff Scientist at Sanford-Burnham Medical Research Institute, contributing to high throughput screening for human genes influencing HIV-1 infection, and as Post-doctoral Research Fellow at Dana-Farber Cancer Institute, where research involved the HIV-1 protein Nef. Kevin's academic background includes a PhD in Microbiology from the University of Virginia and a BS in Molecular Biology from the University of Connecticut.